ValuEngine downgraded shares of BioXcel Therapeutics (NASDAQ:BTAI) from a buy rating to a hold rating in a research report report published on Monday, ValuEngine reports.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright restated a buy rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th. Zacks Investment Research raised shares of GCP Applied Technologies from a sell rating to a hold rating in a report on Friday, May 31st.

NASDAQ BTAI opened at $10.87 on Monday. BioXcel Therapeutics has a 12 month low of $2.41 and a 12 month high of $12.16. The company has a market cap of $170.60 million, a PE ratio of -8.23 and a beta of 3.04. The business’s 50 day moving average price is $10.89. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.59 and a current ratio of 5.59.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Tuesday, May 7th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.02. Sell-side analysts predict that BioXcel Therapeutics will post -2.19 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in BioXcel Therapeutics stock. Creative Planning acquired a new stake in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned approximately 0.20% of BioXcel Therapeutics at the end of the most recent reporting period. 16.05% of the stock is currently owned by institutional investors and hedge funds.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Read More: What is a balanced fund?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.